GlobeNewswire by notified

AGC Biologics Named Manufacturing Company of the year by American Business Awards

Share

Global CDMO honored for Growth in Mammalian, Microbial and Cell and Gene Manufacturing capabilities at Seattle, Boulder and Longmont sites

SEATTLE, June 29, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it was named Company of the Year in the “Large - Manufacturing” category in the 20th Annual American Business Awards®. 

The American Business Awards are the U.S.A.’s premier business awards program. Nicknamed the Stevies for the Greek word meaning “crowned,” the awards were presented to winners at a gala ceremony at the Marriott Marquis Hotel in New York on Monday, June 13. More than 230 professionals worldwide participated in the judging process to select this year’s American Business Award winners. 

AGC Biologics has a global pharmaceutical manufacturing network with seven sites across three continents. Over the last two years, the company has expanded its capabilities and reach within the U.S. and now boasts strong campuses in Seattle, Boulder, Col., and Longmont, Col. Through these investments, AGC Biologics is establishing a reputation as one of the fastest-growing and innovative companies within the life science field.  

The global CDMO added more microbial and mammalian manufacturing lines to its Seattle site, increasing production efficiency. The expansion project eliminated bottlenecking and strengthened services for customers seeking support during the pre-clinical, clinical, and commercial phases of drug production; it also included the addition of a new 500-liter mammalian cell bioreactor to expand manufacturing capacity. The advancements at the Seattle site coincided with AGC Biologics securing more customers at the campus. For example, in 2020, the Seattle site was chosen by Novavax Inc. to produce materials for the company’s COVID-19 vaccine. The campus was also chosen to manufacture materials for a late-stage project for China-based I-MAB Biopharma. 

After acquiring and developing manufacturing sites in Boulder and Longmont over the last two years, AGC Biologics is now one of the largest biotech companies in Colorado. The Boulder facility offers one of the biggest mammalian-drug manufacturing lines in the U.S. and houses two 20,000-liter stainless steel cell bioreactors.  

The Longmont campus is the newest manufacturing site in the company’s global network and serves as AGC Biologics’ North American hub for cell and gene therapy manufacturing. The 622,000-square-foot facility offers cell therapy and viral vector development and manufacturing capabilities. 

At each of its seven global sites, AGC Biologics offers immediate and significant manufacturing capacity for small startup developers and large pharmaceutical companies bringing new biologics products and advanced therapies to market. 

To learn more about AGC Biologics’ global facilities and capabilities, visit https://www.agcbio.com/.  

About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

About the Stevie Awards
Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ObsEva Files Second Quarter 2022 Financial Statements17.8.2022 22:01:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – August 17, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today published its Second Quarter 2022 Financial Statements. The Second Quarter 2022 Financial Statements may be found on the financial section of the Company’s website, here or directly via the link here. About ObsEva ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a clinical pipeline with development programs focused on new therapies for the treatment of preterm labor and improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “O

GOGL - Invitation to presentation of Q2 2022 Results17.8.2022 19:30:59 CEST | Press release

Golden Ocean Group Limited (the “Company) will publish its financial results for the second quarter of 2022 on Thursday August 25, 2022. In connection with the release, a conference call and webcast will be held as described below: Conference call and webcast A conference call will be held at 4:00 P.M. CET (10:00 A.M. New York Time) on Thursday August 25, 2022. The presentation will be available for download from the Investor Relations section at www.goldenocean.bm (under "Presentations") prior to the conference call/webcast. In order to listen to the presentation you may do one of the following: a. Webcast Visit the Investor Relations section of the Company’s website at www.goldenocean.bm and click on the link to “Financial Calendar and Webcast”, or access directly via the webcast link below. GOGL Q2 2022 Webcast b. Conference Call Participants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered. GOGL Q2 2022

Changes in Nokia Corporation's own shares17.8.2022 18:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 17 August 2022 at 19:30 EEST Changes in Nokia Corporation's own shares Espoo, Finland – A total of 189 403 Nokia shares (NOKIA) held by the company were today transferred without consideration to participants of Nokia's equity-based incentive plan in accordance with the rules of the plan. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plan as announced on 3 February 2022. The number of own shares held by Nokia Corporation following the transfer is 79 311 737. About Nokia At Nokia, we create technology that helps the world act together. As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks. We create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs. Adhering to the highest standards of integrity and security, w

Spryker Recognized as a Visionary in 2022 Magic Quadrant™ For Digital Commerce17.8.2022 18:00:00 CEST | Press release

BERLIN and NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Spryker, a leading digital commerce platform for Sophisticated Commerce use cases in B2B, Enterprise Marketplaces, IoT and Unified Commerce, has been recognized by Gartner® as a Visionary in the 2022 Magic Quadrant™ for Digital Commerce. It is Spryker's third consecutive inclusion in the Gartner® Magic Quadrant™ for Digital Commerce. “At Spryker, our goal is to enable digital innovation and differentiation with our composable platform designed specifically for sophisticated transactional business models. We believe being recognized for the second time as a Visionary validates our continued dedication to empowering companies to grow, innovate, and differentiate,” said Boris Lokschin, Co-Founder and CEO at Spryker. “This year we launched our App Composition Platform as the latest stage in our commitment to delivering true composability. This first of its kind platform is why we feel Spryker continues to be recognized in the market. W

Nextensa NV/SA : Half-Year Financial Report 202217.8.2022 17:40:00 CEST | Press release

HALF-YEAR FINANCIAL REPORT 2022 Regulated information Brussels, 17 August 2022 5:40 PM CEST For the first half-year of the financial year 2022 we record the following key data: • The rental income increased by € 3.0 million compared to June last year and now amounts to € 33.2 million • The financial debt ratio has decreased from 48.56% at the end of 2021 to 46.31% on 30 June 2022, in line with the predefined plan • The occupancy rate increased and is now 90.30% compared to 89.09% at the end of 2021 • The extension of the Shopping center Knauf Schmiede welcomes its first shops • The Park Lane phase II project at Tour & Taxis has been launched with a successful reservation of 50% of the apartments of the first section • The construction works on The Emerald office building (7,000 m2) started on Cloche d’Or, a new urban district in the southern outskirts of Luxembourg City Attachment SEMI-AR_2022_ENG_final